Trial Profile
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2020
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 04 Sep 2017 New trial record